4.3 Review

Glucose Homeostasis, Hypoglycemia, and the Burnt-Out Diabetes Phenomenon in Kidney Disease

期刊

SEMINARS IN NEPHROLOGY
卷 41, 期 2, 页码 96-103

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.semnephrol.2021.03.004

关键词

-

资金

  1. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases [K24-DK091419, U01-DK102163, R44-116383, R03-DK114642, R01-DK122767, R01-DK124138]

向作者/读者索取更多资源

Chronic kidney disease is a common and serious complication of diabetes mellitus, contributing significantly to kidney disease burden. Understanding optimal management strategies to reduce cardiovascular risk and improve survival rates is crucial for diabetic patients with CKD.
Chronic kidney disease (CKD) is among the most prevalent and dire complications of diabetes mellitus in adults across the world. Diabetes substantially contributes to the burden of kidney disease, such that one third to one half of CKD in the United States and many other countries is attributable to diabetic kidney disease (DKD). As DKD progresses to end-stage renal disease (ESRD), patients are at heightened risk for atypical glycemic complications, including the development of burnt-out diabetes, manifested by hypoglycemic bouts and poor outcomes. Furthermore, even in the absence of diabetes, hypoglycemia is a frequent occurrence in CKD patients that may contribute to their high burden of cardiovascular disease and death. Extrapolation of data from clinical trials in high cardiovascular-risk populations and observational studies in patients with non-dialysis-dependent (NDD) CKD and ESRD suggest that moderate glycemic targets defined by glycated hemoglobin levels of 6% to 8% and glucose levels of 100 to 150 mg/dL are associated with better survival in DKD patients. However, given the imprecision of glycated hemoglobin levels in kidney disease, further research is needed to determine the optimal glycemic metric and target in diabetic NDD-CKD and ESRD patients. Given their exceedingly high cardiovascular morbidity and mortality, there is a compelling need for further investigation of how to optimally manage dysglycemia in the NDD-CKD and ESRD populations. (C) 2021 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据